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SUMMARY
The WHO recommends hepatitis A virus (HAV) immunization according to level of
transmission and disease burden. We aimed to identify susceptible age groups by standardized
serosurveys to inform HAV vaccination policy in participating countries : Belgium, Czech
Republic, England, Finland, Germany, Italy, Lithuania, Malta, Romania, and Slovakia. Each
country tested national serum banks (n=1854–6748), collected during 1996–2004, for
anti-HAV antibodies. Local laboratory results were standardized to common units. Forty-one
per cent of those aged <30 years and 6% of those aged o30 years were susceptible to HAV in
Romania; compared to 70–94% and 26–71%, respectively, elsewhere. Romania reported high
HAV incidence in children and young adults. Other countries reported HAV disease primarily
in older risk groups. The results suggest low level of HAV transmission in most of Europe.
Romania, however, appeared as an area with intermediate transmission. Vaccination of risk
groups in countries with high susceptibility of young and middle-aged adults needs to be
continued.
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vaccination.
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INTRODUCTION
Hepatitis A virus (HAV) is a non-enveloped positive-
stranded RNA virus of the genus Hepatovirus in the
family Picornaviridae. HAV transmission occurs
mainly through the faecal–oral route, and rarely
through blood-to-blood contact. In countries with
low seroprevalence, specific risk groups for HAV
infection include, e.g. travellers (to endemic regions),
healthcare workers, men who have sex with men
(MSM), injecting drug users (IDUs), and persons re-
ceiving blood products. In children aged <5 years,
HAV infection is usually inapparent, whereas most
adults present with symptoms, with the severity of the
disease increasing with age [1]. The laboratory diag-
nosis of HAV is primarily based on serology. HAV
IgG antibodies persist throughout life, and are a
marker of past immunity. The available inactivated
HAV vaccines are safe and provide long-term pro-
tection. Mathematical modelling predicts antibody
persistence for more than 25 years in over 95% of
vaccine recipients [2]. No specific antiviral treatment
is available for HAV infection.
The age-specific seroprevalence and incidence of
HAV is known to vary geographically. The data
available on age-specific susceptibility to HAV and
average age of infection in Europe are incomplete and
geographically diverse ; for many European countries
no seroepidemiological data are available at all. An
early report comparing seroepidemiological data from
seven European countries indicated higher HAV
seroprevalence in the south of Europe compared to the
north [3]. Since then, improvements in socioecon-
omic and hygienic conditions [4] as well as preventive
interventions, have led to increasing susceptibility to
HAV in children and young adults throughout many
parts of Europe, as reported by sporadic sero-
epidemiological studies by individual European
countries [5–11]. Southern Europe is still estimated to
have a high overall HAV seroprevalence, although
seroprevalence in young adults is declining [12].
The position of the World Health Organization
(WHO) on HAV vaccines emphasizes that the degree
of HAV transmission in a particular country should
guide vaccination policy [13]. In highly endemic
countries, large-scale immunization should not be
undertaken, as most children acquire the (usually
asymptomatic) infection before the age of 10 years,
and subsequently clinical HAV is rare. In countries
with low endemicity and with high rates of disease
in specific high-risk groups, such as IDUs and
travellers, vaccination should be targeted primarily to
these groups. According to the WHO position, it is
the areas with intermediate endemicity, where trans-
mission occurs primarily from person to person in the
general community and often with periodic out-
breaks, where widespread vaccination programmes
should be considered, as in these countries many
individuals escape childhood infection and are
exposed to clinical HAV as adults [13].
In this study the serological results were standard-
ized to produce comparable, age-specific sero-
prevalence estimates of HAV across Europe. Using
these data, the aims of the study were to identify sus-
ceptible age groups and to investigate how these relate
to disease incidence data, in order to inform HAV
vaccination policy in the 10 participating countries.
METHODS
Serum collection
Ten countries participating in the European Sero-
Epidemiology Network 2 (ESEN2) project tested
their national serum banks for total antibodies to
HAV (anti-HAV). Specimens were collected between
1996 and 2004, either as residual sera remaining after
routine laboratory testing (7/10 countries), or by
population-based random sampling (3/10 countries)
(Table 1). Ethical approval of the study protocol was
sought from the appropriate national authorities ac-
cording to national guidelines.
The project guidelines called for an even distri-
bution between males and females of sera that were
also required to be geographically representative for
each country. The guidelines further recommended
the testing of >3000 specimens from all age groups,
of which two-thirds were to be derived from those
aged <20 years. The age-specific numbers were
defined at the start of the ESEN2 project. Table 1
shows the number and age distribution of the col-
lected sera for each country. Sample sizes smaller than
reommended were tested in the Czech Republic,
Lithuania, and Malta. Not all age groups were re-
presented in the serum panels of Germany and
Lithuania.
Organizational analysis : vaccine programme and
hepatitis A incidence
All national representatives completed a standard-
ized electronic questionnaire regarding the HAV
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vaccination programme in effect in each participant
country in March 2002 (Table 2). Disease incidence
by age since 1970 was requested as well as information
on whether the reported incidence represented
laboratory-confirmed cases or clinical notifications.
Updated information was requested in 2010.
Assay standardization
The procedure followed to standardize the antibody
results has been described in detail elsewhere [14, 15].
Briefly, a standardization panel of 150 sera was de-
veloped by a designated reference laboratory (the
National Retrovirus Reference Center, University of
Athens Medical School, Greece), to include specimens
with antibody titres ranging from negative and
equivocal (low positive) to high positive. This panel
was tested by the participating national laboratories
for total anti-HAV antibodies using assays of their
choice. Each country’s results were subsequently
regressed against those of the reference laboratory,
obtained with HAVAB 2.0 quantitative test on the
AxSYM system (Abbott Laboratories, USA). The
standardization equations were then used to convert
titres from local (national) tests to standard units. The
R2 (the square of the multiple correlation coefficient)
was used to evaluate the standardization of the assays
[14, 15]. For situations where the proportion of the
variability in the data explained by the regression
model was too low, the equations were deemed inef-
ficient and were excluded from the study.
Since the main serum banks of Germany and
England had already been tested over a year before
the distribution of the standardization panel (Table 1),
an alternative method termed ‘back-standardization’
described in detail elsewhere [15] was undertaken. In
brief, a subset of about 150 titre-stratified (negative,
low positive, positive) specimens from the country’s
main serum bank was tested by the reference labora-
tory with its established assay. Standardization was
then performed as described above after a regression
analysis on the two generated datasets [14].
Main serum bank testing and data analysis
Each country used the same assay to test the stan-
dardization panel and the main serum banks. After
the main bank results were transformed into stan-
dardized reference laboratory units, they were re-
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RESULTS
Standardization was successful for the ten countries
included in this study: Belgium, Czech Republic,
England, Finland, Germany, Italy, Lithuania, Malta,
Romania, and Slovakia [14]. The susceptibility to
HAV decreased in the older age groups in all partici-
pating countries (Table 3). The overall susceptibility
was lowest in Romania and highest in Finland. In the
o30 years age group, 6% were susceptible in
Romania, 26% in Malta, 28% in Italy, 41% in
Slovakia, 46% in Germany, 48% in England, 50%
in Belgium, 54% in Czech Republic, and 71% in
Finland. Data were missing for Lithuania. In the<30
years age group, 42% were susceptible in Romania,
compared to 70–94% in the other countries (Table 3).
There was >80% susceptibility throughout the
<50 years age group in Finland; <40 years in Czech
Republic ; <30 years in Belgium, England, Germany,
Italy, Slovakia, and <10 years in Lithuania and
Malta. A <40% susceptibility was seen throughout
the o10 years age group in Romania; o40 years
in Malta and Italy, o50 years in Belgium, Czech
Republic, England, Germany, Slovakia; and o60
years in Finland. The median age of infection was
lowest in Romania (10 years), and ranged from 35 to
56 years in the other countries (not calculated for
Lithuania due to missing data in older age groups)
(Table 3).
Figure 1 shows the seroprevalence of HAV in the
participating countries by birth cohort. The sero-
prevalence fell below 20% in the birth cohorts of the
early 1950s in Finland; mid-1960s in Czech Republic
and Germany; late 1960s in Italy ; mid-1970s in
England and Slovakia; and early 1990s in Belgium
and Malta. In Lithuania and Romania the sero-
prevalence was >20% in all birth cohorts (data not
available for those aged >30 years in Lithuania).
Table 3 shows the reported HAV incidence for all
participating countries (when reported data were
available). The highest incidence was reported in
Romania (283/100 000). The incidence varied between
0.3–54/100 000 population in the other countries (data
for Lithuania unavailable).
Examining more closely Romania and Finland
(Figs 2, 3), countries which represent the two extremes
in this study, several differences can be observed.
Romania showed an y70% seroprevalence in those
aged<1 year; the seroprevalence in women of typical
childbearing age (20–39 years) was 85% (data not
shown), whereas in Finland, the respective sero-
prevalence was 6% and 5% (data not shown). In
Romania, the lowest seroprevalence was seen in those
aged 1–10 years, varying between 28% and 49%,







HCW Other* IDU MSM Travellers Other
Chronic liver
disease Haemophilia Other
Belgium 3 3 3 3 3
Czech Republic 3
England 3 3 3 3 3 3 3
Finland 3 3 3 3 3 3
Germany 3 3 3 3 3 3 3· 3
Italy 3 3 3 3# 3 3 3· 3
Lithuania 3 3
Malta 3 3 3 3#
Romania 3
Slovakia 3 3 3 3 3$ 3 3
HCW, Healthcare worker ; IDU, injecting drug user ; MSM, men who have sex with men.
* Including, e.g. laboratory workers at risk, sewage workers, workers in institutions for the care of mentally or behaviourally
disabled, workers in childcare institutions, canal workers, food handlers, workers in hospital laundry, people who work with
primates.
# Military and diplomatic staff posted abroad.
$ Children living in unhygienic conditions.
· Non-immune patients with chronic hepatitis B or C virus infection.
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after which age the seroprevalence remained above
50%, steeply increasing towards the older age groups,
reaching 97% in those aged 50–59 years (Fig. 2).
According to the data provided by the country for the
ESEN2 project, in the specimen collection year 2002,
the highest HAV disease incidence in Romania was in
the 5–19 years age group (152–285/100 000) (Fig. 2),
whereas in the other participating countries the re-
spective incidence remained <60/100 000 (age-
specific data from 2002 not available for Belgium,
Lithuania, and Malta). In Finland, seroprevalence
remained low throughout the 0–39 years age groups,
varying between 2% and 10%, and thereafter in-
creasing towards the older age groups, reaching 40%
in the 50–59 years age group, and 73% in those aged
o60 years. According to the data from the Finnish
infectious diseases registry, during the specimen col-
lection years 1997–1998, the incidence was highest in
those aged 10–39 years (4–6/100 000) (Fig. 3a). In
2002, when an outbreak in IDUs was reported, the
overall incidence was highest in those aged 15–34
years (12–22/100 000) (Fig. 3a). Comparing the over-
all incidence of the two countries over time, the inci-
dence was 9–272 times higher in Romania than in
Finland during 1988–2009, with a decreasing trend
over time in Romania (Figs 2b, 3b).
DISCUSSION
This comparative, population-based seroepidemi-
ological study demonstrates that in most European
countries included in this study, i.e. Belgium, Czech
Republic, England, Finland, Germany, and Slovakia,
there was a high susceptibility to HAV in children
and young adults, and moderate susceptibility in
older adults. In Malta and Italy, there was high sus-
ceptibility in children and young adults, but older
adults showed low susceptibility. Romania differed
from the other participating countries by showing
a low overall susceptibility to HAV, and high di-
sease incidence, particularly in children and young
adults.
A major strength of this study is the direct com-
parability of the anti-HAV antibody test results be-
tween countries, which was achieved through the data
standardization procedure. However, there are a
number of limitations to this study. The serological
tests used for the detection of anti-HAV antibodies
do not distinguish between natural and vaccine
immunity, and the seroprevalence data therefore rep-







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 1. Seroprevalence of HAV in the participating countries by birth cohort : (a) Czech Republic, Finland, Germany,
England; (b) Belgium, Italy, Malta, Slovakia ; (c) Lithuania and Romania. The data in these panels are based on the
following age groups: 0–4, 5–9, 10–14, 15–19, 20–24, 25–29, 30–34, 35–39, 40–49, 50–59, and o60 years. The data points
represent the median birth year of each group, except for the end points which represent the end point birth year and all those
born before that.
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with regard to vaccine uptake. Furthermore, the data
were collected in different years in the participating
countries, which complicate their temporal compara-
bility. Not all age groups were represented in all of the
countries. Although the standardization procedure
was generally successful, it was considered unsatis-
factory for the countries that had to be excluded [14].
It is also possible that the seroprevalence profiles in
some of the countries may have changed since the
collection of the data for this study. Furthermore, the
information collected from the countries on reported
cases was in some cases incomplete and was based on
clinical and laboratory-based reporting using differ-
ent case definitions, and therefore caution is advised
when interpreting and comparing incidence estimates
between countries.
Many of the participating countries have pre-
viously reported sporadic HAV seroprevalence data in
the literature [5–11, 16, 17]. The previously available
data are in line with the present study. However,
for Lithuania, Malta, Romania, and Slovakia,
almost no internationally published information was
available on HAV seroprevalence, and for other
countries the data were not comparable to each other.
This study provides new insights into the comparative
seroepidemiology of HAV in these countries.
Analysis of HAV seroprevalence by birth cohort in
each participating country (Fig. 1) showed that in
Finland and England, endemic circulation of HAV
continued until the early 1960s. Endemic circulation
in Germany and Czech Republic persisted until the
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Fig. 2. Characteristics of HAV seroepidemiology in Romania. HAV seroprevalence in 2002 and age-specific incidence in
(a) 2002, and (b) overall incidence over time. In panel (a), the age-specific incidence data are based on the following age
groups : <1, 1, 2, 3, 4, 5–9, 10–14, 15–19, 20–24, 25–34, 35–44, 45–54, 55–65, 65–74, 75–84, o85 years, and the age-specific
prevalence data are based on the following age groups: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20–24,
25–29, 30–34, 35–39, 40–49, 50–59, o60 years. The data points represent the median age of each group, except for the end
points, which represent the end point age and all those older than that.
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higher seroprevalence profile throughout the birth
cohorts. In contrast, in Belgium, Italy, and Slovakia,
the endemic circulation continued well until the end
of 1960s. In Lithuania, a trend towards increasing
seroprevalence was noted after age 10 years (birth
cohort 1993) ; however, data were not available for
those aged >30 years. The very high seroprevalence
across all birth cohorts clearly distinguished the
seroprevalence profile of Romania from the other
participating countries.
The HAV seroprofiles in birth cohorts to some ex-
tent appear to reflect changes in hygienic and socio-
economic conditions in different countries over time.
Indicative of historic transmission, all participating
countries showed high seroprevalence in the elderly.
In Finland, seroprevalence fell below 40% in early
1940s, which approximately coincides with the end of
the war in that country.
HAV IgG antibodies pass through the placenta to


















































































































































Fig. 3. Characteristics of HAV seroepidemiology in Finland. (a) HAV seroprevalence in 1997–1998, and age-specific inci-
dence in 1997–1998 (combined) and in 2002 (when HAV outbreak in intravenous drug users occurred in Finland. (b) Overall
incidence over time.
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Usually maternal antibodies disappear by age 6
months, after which children become susceptible,
and are at significant risk of infection in an area with
endemic circulation of HAV. The susceptibility
of newborns was demonstrated here by comparing
Romania and Finland. In Romania, the high
seroprevalence in women of childbearing age was re-
flected by the presence of maternally acquired anti-
bodies in the majority of infants. In Finland, the
susceptibility in women of childbearing age was high,
leading to low seroprevalence in newborns.
The high susceptibility to HAV in young and
middle-aged adults demonstrated in this study for
most of the participating countries is reflected by nu-
merous reports of outbreaks in both high-risk groups
and the general population in Europe. Outbreaks in
IDUs have occurred, e.g. in England [18], Finland
[19], Italy [20], and The Netherlands [21], and in
MSM, e.g. in Denmark [22], Norway [23], and Spain
[24]. Outbreaks related to contamination from food
and/or food handlers have been reported, e.g. in
Belgium [25], Germany [26], Finland [27] and Italy
[28]. Travellers to endemic areas are typical risk
groups in countries with high susceptibility. Onward
transmission after recent travel to an endemic area is
occasionally seen in countries with low endemicity
[29–32]. Community-wide outbreaks, often related to
poor hygienic conditions have been reported, e.g. in
Bulgaria, Italy, Latvia, and Slovakia [33–38]. It is
evident that vaccination of risk groups in countries
with high susceptibility of young and middle-aged
adults needs to be continued.
Previous reports suggest a changing epidemiology
of HAV in Southern Europe, with outbreaks in young
adults due to their increasing susceptibility to HAV
[39, 40]. Our study suggests this phenomenon for both
Italy and Malta. While those aged o30 years still
show a low susceptibility to HAV, children and young
adults already show a high susceptibility in these two
countries.
All other countries except Romania offer HAV
vaccination to various high-risk groups. There is a
degree of variability between countries (Table 2) as
to the targeted groups, related to occupation (e.g.
healthcare workers), lifestyle (e.g. travellers, MSM,
and IDUs), and underlying medical condition (e.g.
haemophiliacs). The policy of all countries except
Belgium, Italy, and Malta also included immuniz-
ation as an outbreak control measure (Table 2).
In conclusion, serosurveys can be used to inform
HAV vaccine policy of countries. Romania can be
characterized as an area with intermediate HAV en-
demicity, for which, according the WHO position
[13], a nationwide vaccination programme should be
considered. All other countries participating in this
study are areas of low endemicity, in which targeted
vaccination of high-risk groups needs to be continued,
in accordance with the WHO recommendation. We
have further demonstrated here the continuously
changing epidemiology of HAV across Europe. Good
surveillance systems need to be maintained to monitor
these trends, and to implement the appropriate HAV
immunization policies.
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